News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

airPharma Signs Agreement With Britannia Pharmaceuticals Limited To Bring Novel Asthma Treatment To Market


10/19/2005 5:12:07 PM

airPharma and Britannia Pharmaceuticals Limited today announced that they have signed a global licensing agreement in which airPharma will develop AP0016, a dry powder formulation of Britannia's synthetic surfactant, Pumactant. Under the terms of the agreement, airPharma will initiate a clinical program to study the drug's efficacy for seasonal allergic asthma, followed by additional respiratory indications such as perennial allergic asthma and chronic obstructive pulmonary disease (COPD). airPharma will also assume control of regulatory and marketing initiatives for AP0016 as well as activities related to the eventual commercialization of the product worldwide, except for the United Kingdom and Ireland, which will remain under Britannia's management.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES